免疫检查点VISTA在消化系统疾病中的研究进展
Research Progress of Immune Checkpoint VISTA in Digestive System Diseases
DOI: 10.12677/md.2026.161011, PDF,   
作者: 赵艳革：济宁医学院临床医学院(附属医院)，山东 济宁；王韶轩*：济宁市第一人民医院消化内科，山东 济宁
关键词: VISTA；炎症性肠病；消化道肿瘤；作用机制；VISTA； Inflammatory Bowel Disease； Gastrointestinal Tumors； Mechanism of Action
摘要: T细胞活化V结构域免疫球蛋白抑制因子(VISTA)是一种新的免疫检查点，在调节免疫反应中发挥重要作用，VISTA可能通过影响免疫细胞的活性，特别是调节T细胞的功能，对消化系统疾病的发展产生重要影响。VISTA通过调节T细胞的功能来维持免疫耐受性，在消化系统疾病中，特别是对炎症性肠病(IBD)和消化道肿瘤的免疫调节，VISTA可能发挥着重要作用。目前很多研究表明，VISTA不仅在免疫调节和肿瘤微环境中发挥重要作用，而且在维持免疫稳态和缓解炎症性疾病中也具有重要价值。本文主要讨论了VISTA的分子结构及功能机制，重点分析其在炎症性疾病和消化系统肿瘤中的研究进展，阐述了VISTA与消化系统疾病的关系，目的是为消化系统疾病的发病机制及治疗提供新的思路。
Abstract: T cell activation V-domain-containing immunoglobulin-like inhibitory protein (VISTA) is a recently discovered immune checkpoint that plays an exceptionally important role in regulating immune responses. VISTA may affect immune cell activity and modulate T cell function, then significantly influence the progression of gastrointestinal diseases. T cell function can be regulated to help VISTA maintain immune tolerance. In gastrointestinal diseases, particularly inflammatory bowel disease (IBD) and gastrointestinal tumors, VISTA probably plays a key role in immune regulation. Many studies have shown that VISTA functions significantly in immune regulation and the tumor microenvironment; meanwhile, it has a great impact on maintaining immune homeostasis and alleviating inflammatory diseases. This paper discusses the molecular structure and functional mechanisms of VISTA, focusing on its research progress in inflammatory diseases and gastrointestinal tumors. It explains the relationship between VISTA and gastrointestinal diseases, for the purpose of providing new insights into the pathogenesis and treatment of these conditions.
文章引用：赵艳革, 王韶轩. 免疫检查点VISTA在消化系统疾病中的研究进展[J]. 医学诊断, 2026, 16(1): 72-79. https://doi.org/10.12677/md.2026.161011

参考文献

[1] Deng, Y., Shi, M., Yi, L., Naveed Khan, M., Xia, Z. and Li, X. (2024) Eliminating a Barrier: Aiming at VISTA, Reversing MDSC-Mediated T Cell Suppression in the Tumor Microenvironment. Heliyon, 10, e37060. [Google Scholar] [CrossRef] [PubMed]
[2] Tagliamento, M., Agostinetto, E., Borea, R., Brandão, M., Poggio, F., Addeo, A., et al. (2021) VISTA: A Promising Target for Cancer Immunotherapy? ImmunoTargets and Therapy, 10, 185-200. [Google Scholar] [CrossRef] [PubMed]
[3] Hosseinkhani, N., Derakhshani, A., Shadbad, M.A., Argentiero, A., Racanelli, V., Kazemi, T., et al. (2021) The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead. Frontiers in Immunology, 12, Article 676181. [Google Scholar] [CrossRef] [PubMed]
[4] Tang, X., Xiong, Y., Shi, X., Zhao, Y., Shi, A., Zheng, K., et al. (2022) IGSF11 and VISTA: A Pair of Promising Immune Checkpoints in Tumor Immunotherapy. Biomarker Research, 10, Article No. 49. [Google Scholar] [CrossRef] [PubMed]
[5] Mehta, N., Maddineni, S., Mathews, I.I., Andres Parra Sperberg, R., Huang, P. and Cochran, J.R. (2019) Structure and Functional Binding Epitope of V-Domain Ig Suppressor of T Cell Activation. Cell Reports, 28, 2509-2516.e5. [Google Scholar] [CrossRef] [PubMed]
[6] Emaldi, M., Alamillo-Maeso, P., Rey-Iborra, E., Mosteiro, L., Lecumberri, D., Pulido, R., et al. (2024) A Functional Role for Glycosylated B7-H5/VISTA Immune Checkpoint Protein in Metastatic Clear Cell Renal Cell Carcinoma. iScience, 27, Article ID: 110587. [Google Scholar] [CrossRef] [PubMed]
[7] Wang, G., Tai, R., Wu, Y., Yang, S., Wang, J., Yu, X., et al. (2020) The Expression and Immunoregulation of Immune Checkpoint Molecule VISTA in Autoimmune Diseases and Cancers. Cytokine & Growth Factor Reviews, 52, 1-14. [Google Scholar] [CrossRef] [PubMed]
[8] Gao, Y., He, Y., Tang, Y., Chen, Z. and Qu, M. (2024) VISTA: A Novel Checkpoint for Cancer Immunotherapy. Drug Discovery Today, 29, Article ID: 104045. [Google Scholar] [CrossRef] [PubMed]
[9] Kuklinski, L.F., Yan, S., Li, Z., Fisher, J.L., Cheng, C., Noelle, R.J., et al. (2018) VISTA Expression on Tumor-Infiltrating Inflammatory Cells in Primary Cutaneous Melanoma Correlates with Poor Disease-Specific Survival. Cancer Immunology, Immunotherapy, 67, 1113-1121. [Google Scholar] [CrossRef] [PubMed]
[10] Zhang, Y., Zhang, X., Han, J., Guo, Y., Yang, F., Li, F., et al. (2023) Downregulated VISTA Enhances Th17 Differentiation and Aggravates Inflammation in Patients with Acute-On-Chronic Liver Failure. Hepatology International, 17, 1000-1015. [Google Scholar] [CrossRef] [PubMed]
[11] Ren, R., Chang, X., Chen, C., Yu, H. and Han, L. (2023) VISTA as a Prospective Immune Checkpoint in Gynecological Malignant Tumors: A Review of the Literature. Open Medicine, 18, Article ID: 20230866. [Google Scholar] [CrossRef] [PubMed]
[12] Zhu, Z., Ding, R., Yu, W., Liu, Y., Zhou, Z. and Liu, C. (2025) YAP/TEAD4/SP1-Induced VISTA Expression as a Tumor Cell-Intrinsic Mechanism of Immunosuppression in Colorectal Cancer. Cell Death & Differentiation, 32, 911-925. [Google Scholar] [CrossRef] [PubMed]
[13] ElTanbouly, M.A., Zhao, Y., Nowak, E., Li, J., Schaafsma, E., Le Mercier, I., et al. (2020) VISTA Is a Checkpoint Regulator for Naïve T Cell Quiescence and Peripheral Tolerance. Science, 367, eaay0524. [Google Scholar] [CrossRef] [PubMed]
[14] ElTanbouly, M.A., Zhao, Y., Schaafsma, E., Burns, C.M., Mabaera, R., Cheng, C., et al. (2021) VISTA: A Target to Manage the Innate Cytokine Storm. Frontiers in Immunology, 11, Article 595950. [Google Scholar] [CrossRef] [PubMed]
[15] Wang, S., Su, W., Wu, X. and Dong, W. (2024) Restoring Treg/Th17 Cell Balance in Ulcerative Colitis through HRas Silencing and MAPK Pathway Inhibition. International Immunopharmacology, 130, Article ID: 111608. [Google Scholar] [CrossRef] [PubMed]
[16] Brand, S. (2009) Crohn’s Disease: Th1, Th17 or Both? The Change of a Paradigm: New Immunological and Genetic Insights Implicate Th17 Cells in the Pathogenesis of Crohn’s Disease. Gut, 58, 1152-1167. [Google Scholar] [CrossRef] [PubMed]
[17] Schnell, A., Littman, D.R. and Kuchroo, V.K. (2023) TH17 Cell Heterogeneity and Its Role in Tissue Inflammation. Nature Immunology, 24, 19-29. [Google Scholar] [CrossRef] [PubMed]
[18] Huangfu, L., Li, R., Huang, Y. and Wang, S. (2023) The IL-17 Family in Diseases: From Bench to Bedside. Signal Transduction and Targeted Therapy, 8, Article No. 402. [Google Scholar] [CrossRef] [PubMed]
[19] Lines, J.L., Pantazi, E., Mak, J., Sempere, L.F., Wang, L., O’Connell, S., et al. (2014) VISTA Is an Immune Checkpoint Molecule for Human T Cells. Cancer Research, 74, 1924-1932. [Google Scholar] [CrossRef] [PubMed]
[20] Zheng, M., Zhang, Z., Yu, L., Wang, Z., Dong, Y., Tong, A., et al. (2023) Immune-Checkpoint Protein VISTA in Allergic, Autoimmune Disease and Transplant Rejection. Frontiers in Immunology, 14, Article 1194421. [Google Scholar] [CrossRef] [PubMed]
[21] Li, M., Chen, B., Wang, Z., Guo, R., Xiong, N., Qian, Y., et al. (2025) Macrophage-Derived VISTA Engages with LRIG1 and Hinders Gut Epithelial Repair in Colitis. Cellular & Molecular Immunology, 22, 1379-1397. [Google Scholar] [CrossRef] 
[22] 吴昊宇, 蒋敬庭. 新型免疫检查点分子VISTA的研究进展[J]. 中国肿瘤生物治疗杂志, 2024, 31(3): 283-288.
[23] Niu, X., Li, B., Luo, F., Li, W., Zhou, X. and Zhao, W. (2025) VISTA as a Context-Dependent Immune Checkpoint: Implications for Tumor Immunity and Autoimmune Pathogenesis. Biochimica et Biophysica Acta (BBA)—Reviews on Cancer, 1880, Article ID: 189351. [Google Scholar] [CrossRef] [PubMed]
[24] Cao, Y., Yu, K., Zhang, Z., Gu, Y., Gu, Y., Li, W., et al. (2024) Blockade of V‐Domain Immunoglobulin Suppressor of T‐Cell Activation Reprograms Tumour‐Associated Macrophages and Improves Efficacy of PD‐1 Inhibitor in Gastric Cancer. Clinical and Translational Medicine, 14, e1578. [Google Scholar] [CrossRef] [PubMed]
[25] Chmiel, P., Gęca, K., Michalski, A., Kłosińska, M., Kaczyńska, A., Polkowski, W.P., et al. (2023) Vista of the Future: Novel Immunotherapy Based on the Human V-Set Immunoregulatory Receptor for Digestive System Tumors. International Journal of Molecular Sciences, 24, Article 9945. [Google Scholar] [CrossRef] [PubMed]
[26] Choi, S., Kim, H., Heo, Y.J., Kang, S.Y., Ahn, S., Lee, J., et al. (2023) PIK3CA Mutation Subtype Delineates Distinct Immune Profiles in Gastric Carcinoma. The Journal of Pathology, 260, 443-454. [Google Scholar] [CrossRef] [PubMed]
[27] ElTanbouly, M.A., Schaafsma, E., Noelle, R.J. and Lines, J.L. (2020) VISTA: Coming of Age as a Multi-Lineage Immune Checkpoint. Clinical and Experimental Immunology, 200, 120-130. [Google Scholar] [CrossRef] [PubMed]
[28] Deng, J., Li, J., Sarde, A., Lines, J.L., Lee, Y., Qian, D.C., et al. (2019) Hypoxia-Induced VISTA Promotes the Suppressive Function of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. Cancer Immunology Research, 7, 1079-1090. [Google Scholar] [CrossRef] [PubMed]
[29] Hou, Z., Pan, Y., Fei, Q., Lin, Y., Zhou, Y., Liu, Y., et al. (2020) Prognostic Significance and Therapeutic Potential of the Immune Checkpoint VISTA in Pancreatic Cancer. Journal of Cancer Research and Clinical Oncology, 147, 517-531. [Google Scholar] [CrossRef] [PubMed]
[30] Zong, L., Yu, S., Mo, S., Zhou, Y., Xiang, Y., Lu, Z., et al. (2020) High VISTA Expression Correlates with a Favorable Prognosis in Patients with Colorectal Cancer. Journal of Immunotherapy, 44, 22-28. [Google Scholar] [CrossRef] [PubMed]
[31] Thakkar, D., Paliwal, S., Dharmadhikari, B., Guan, S., Liu, L., Kar, S., et al. (2022) Rationally Targeted Anti-Vista Antibody That Blockades the C-C’ Loop Region Can Reverse VISTA Immune Suppression and Remodel the Immune Microenvironment to Potently Inhibit Tumor Growth in an Fc Independent Manner. Journal for ImmunoTherapy of Cancer, 10, e003382. [Google Scholar] [CrossRef] [PubMed]
[32] Yuan, L., Tatineni, J., Mahoney, K.M. and Freeman, G.J. (2021) VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy. Trends in Immunology, 42, 209-227. [Google Scholar] [CrossRef] [PubMed]
[33] Zhang, R.J. and Kim, T.K. (2024) VISTA-Mediated Immune Evasion in Cancer. Experimental & Molecular Medicine, 56, 2348-2356. [Google Scholar] [CrossRef] [PubMed]
[34] Martin, A.S., Molloy, M., Ugolkov, A., von Roemeling, R.W., Noelle, R.J., Lewis, L.D., et al. (2023) VISTA Expression and Patient Selection for Immune-Based Anticancer Therapy. Frontiers in Immunology, 14, Article 1086102. [Google Scholar] [CrossRef] [PubMed]
[35] Shekari, N., Shanehbandi, D., Kazemi, T., Zarredar, H., Baradaran, B. and Jalali, S.A. (2023) VISTA and Its Ligands: The Next Generation of Promising Therapeutic Targets in Immunotherapy. Cancer Cell International, 23, Article No. 265. [Google Scholar] [CrossRef] [PubMed]
[36] Schaafsma, E., Croteau, W., ElTanbouly, M., Nowak, E.C., Smits, N.C., Deng, J., et al. (2022) VISTA Targeting of T-Cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance. Cancer Immunology Research, 11, 38-55. [Google Scholar] [CrossRef] [PubMed]
[37] Tao, T., Bo, L., Li, T., Shi, L., Zhang, H., Ye, B., et al. (2021) High‐Affinity Anti‐Vista Antibody Protects against Sepsis by Inhibition of T Lymphocyte Apoptosis and Suppression of the Inflammatory Response. Mediators of Inflammation, 2021, Article ID: 6650329. [Google Scholar] [CrossRef] [PubMed]
[38] Topcu, K.S.B. and Cacan, E. (2025) Twist1 Regulates the Immune Checkpoint vista and Promotes the Proliferation, Migration and Progression of Pancreatic Cancer Cells. Journal of Cellular and Molecular Medicine, 29, e70586. [Google Scholar] [CrossRef] [PubMed]
[39] Jung, M. and Bonavida, B. (2022) Targeting the V-Type Immunoglobulin Domain-Containing Suppressor to T Cell Activation (VISTA) with Agonist Monoclonal Antibodies in Autoimmunity. Critical Reviews in Immunology, 42, 37-49. [Google Scholar] [CrossRef] [PubMed]
[40] Noelle, R.J., Lines, J.L., Lewis, L.D., Martell, R.E., Guillaudeux, T., Lee, S.W., et al. (2023) Clinical and Research Updates on the VISTA Immune Checkpoint: Immuno-Oncology Themes and Highlights. Frontiers in Oncology, 13, Article 1225081. [Google Scholar] [CrossRef] [PubMed]
[41] Iadonato, S., Ovechkina, Y., Lustig, K., Cross, J., Eyde, N., Frazier, E., et al. (2023) A Highly Potent Anti-Vista Antibody KVA12123—A New Immune Checkpoint Inhibitor and a Promising Therapy against Poorly Immunogenic Tumors. Frontiers in Immunology, 14, Article 1311658. [Google Scholar] [CrossRef] [PubMed]
[42] Jiang, M., Bennani, N.N. and Feldman, A.L. (2017) Lymphoma Classification Update: T-Cell Lymphomas, Hodgkin Lymphomas, and Histiocytic/dendritic Cell Neoplasms. Expert Review of Hematology, 10, 239-249. [Google Scholar] [CrossRef] [PubMed]
[43] Wu, C., Cao, X. and Zhang, X. (2021) VISTA Inhibitors in Cancer Immunotherapy: A Short Perspective on Recent Progresses. RSC Medicinal Chemistry, 12, 1672-1679. [Google Scholar] [CrossRef] [PubMed]